在CTEPH的气球肺血管整形术的演变和新视角
Julia Larsen1, Vladimir Lakhter1, Amine Nasri1
1Department of Cardiovascular Diseases, Temple University Hospital, Philadelphia, PA 19140, USA.
Journal of clinical medicine
|February 13, 2025
概括
气球肺血管整形 (BPA) 为慢性血栓栓塞性肺病 (CTEPD) 和高血压 (CTEPH) 提供了一种不那么侵入性的治疗方法,当手术不可行时. 本综述涵盖了BPA在管理这些复杂的肺部疾病方面的指示,技术和结果.
科学领域:
- 心脏病学 心脏病学
- 肺部医学 肺部医学
- 干预性放射学 干预性放射学
背景情况:
- 慢性血栓栓塞性肺病 (CTEPD) 和肺高血压 (CTEPH) 由未解决的肺栓塞 (PE) 引起,导致肺动脉纤维化和阻塞.
- 这导致右心室后负荷增加,右侧心力衰竭,如果不治疗,可能导致死亡.
- 目前的治疗方法,如肺内关节切除术 (PTE),对于近位疾病是有效的,但对远位疾病是有限的,而血管扩展剂可以治疗微血管病变,但不能治疗阻塞性纤维化病变.
研究的目的:
- 审查气球肺血管整形术 (BPA) 在治疗CTEPH和CTEPD的当代使用情况.
- 讨论目前的适应症,患者选择标准和BPA的技术方面.
- 概述BPA的结果,潜在的并发症和未来的研究方向.
主要方法:
- 本综述综合了关于BPA用于CTEPH的当前文献和临床经验.
- 它侧重于患者选择,手术技术和手术后管理.
- 分析了与BPA相关的结果和并发症.
主要成果:
- BPA是一种使用血管塑造来缓解肺动脉阻塞的皮肤通透再血管化疗法.
- 它针对较大的肺动脉中纤维化病变,不易受到PTE或血管扩张剂的影响.
- 该审查详细介绍了当代BPA程序的有效性和安全性.
结论:
- 在CTEPH和CTEPD的管理中,BPA代表了显著的进步,特别是在复杂或远端疾病中.
- 它为不适合PTE的患者提供了潜在的治愈选择.
- 需要进一步的研究来优化BPA技术并扩大其应用.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
166
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
166
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
145
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
145
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131
Pulmonary Hypertension: Classification and Pathogenesis
147
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
147
Pneumothorax-II
117
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
117


